Related Experiment Video

Updated: Mar 25, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Drug Resistance to EGFR Inhibitors in Lung Cancer

Osamu Tetsu, Matthew J Hangauer, Janyaporn Phuchareon

    Chemotherapy
    |February 25, 2016
    PubMed
    Abstract

    Insights

    Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a major challenge in non-small-cell lung cancer (NSCLC). Combination therapies are crucial for overcoming resistance and improving patient outcomes.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Epidermal growth factor receptor (EGFR) mutations have revolutionized non-small-cell lung cancer (NSCLC) treatment.
    • EGFR-targeted therapies offer significant promise but face challenges due to drug resistance.
    • Drug resistance remains a substantial issue in NSCLC treatment.

    Purpose of the Study:

    • To review the literature on drug resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC.
    • To provide an overview of primary, acquired, and persistent drug resistance.
    • To inform the development of more effective therapeutic strategies.

    Main Methods:

    • Literature review of studies on EGFR TKI resistance in NSCLC.
    • Analysis of various drug resistance mechanisms.
    • Synthesis of findings to guide clinical practice.

    Main Results:

    • Mechanisms of primary, acquired, and persistent drug resistance to TKIs are diverse.
    • Sequential use of single agents is challenging for overcoming resistance.
    • Multidrug combinations are essential for effective treatment strategies.

    Conclusions:

    • Accurate diagnosis of drug resistance is critical for personalized treatment.
    • Combination therapy is necessary to overcome patient-specific drug resistance.
    • Precision medicine requires tailored therapeutic approaches for NSCLC patients.

    More Related Videos

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    8.5K
    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    4.7K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.4K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    66
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    544